Learning Center

Your central location for online learning and education surrounding all aspects of tissue donation, tissue banking, research and transplantation.

Back to Search by Speaker

Mohammad Albanna, PhD

Mohammad Albanna, PhD

CEO & Founder, Humabiologics, Inc

Dr. Albanna is the founder and CEO of Humabiologics, one of the only regenerative medicine companies focused on developing and commercializing human-derived biomaterials to researchers around the world for regenerative medicine applications. He holds a PhD in Biomedical Engineering, 2 master’s degrees in Materials Sciences and Electrical & Computer Engineering and completed a postdoctoral fellowship at Wake Forest Institute of Regenerative Medicine, where he served as the lead of the skin bioprinting group and is currently an adjunct assistant professor of Surgery at Atrium Health Wake Forest Baptist. Dr. Albanna authored several peer-reviewed papers, book chapters and is the inventor of several issued and patent-pending applications. Dr. Albanna has 15 years of industry experience, during which he has held several senior and executive leadership positions across several industries including medical devices, blood banking, and tissue banking. His work in regenerative medicine was recognized through several prestigious awards including the 2013 Thomas Edison Gold Award in Innovation, 2018 Arizona Innovator of the year finalist, and 2021 Arizona Leader in Innovation Award.

Content Where I Am Featured

Search by Format
Sort By
Search by Favorites

  • How Allograft Tissue Empowers Development of Future Regenerative Therapies (Individual)
    Contains 3 Component(s)

    Over the past several decades, allografts have been the gold standard for regenerative medicine when it comes to patient recovery and safety. These allografts come from donated human tissues such as skin and bone, which make them an obvious choice for the repair of similar tissues. However, due to the inherited biological, physical, and chemical properties, manipulating their characteristics remain a challenge. In this talk, Dr. Albanna will discuss Humabiologics’ role in extending the gift of donated human tissues and how allografts continue to impact and advance various regenerative therapies through bioprinting, creating relevant human tissue and diseases models for drug discovery and testing, and many other applications.

  • How Allograft Tissue Empowers Development of Future Regenerative Therapies (Group)
    Contains 3 Component(s)

    Over the past several decades, allografts have been the gold standard for regenerative medicine when it comes to patient recovery and safety. These allografts come from donated human tissues such as skin and bone, which make them an obvious choice for the repair of similar tissues. However, due to the inherited biological, physical, and chemical properties, manipulating their characteristics remain a challenge. In this talk, Dr. Albanna will discuss Humabiologics’ role in extending the gift of donated human tissues and how allografts continue to impact and advance various regenerative therapies through bioprinting, creating relevant human tissue and diseases models for drug discovery and testing, and many other applications.